Brigid C. Browne

1.3k total citations
22 papers, 969 citations indexed

About

Brigid C. Browne is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Brigid C. Browne has authored 22 papers receiving a total of 969 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Molecular Biology. Recurrent topics in Brigid C. Browne's work include HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Advanced Breast Cancer Therapies (4 papers). Brigid C. Browne is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Advanced Breast Cancer Therapies (4 papers). Brigid C. Browne collaborates with scholars based in Ireland, United States and Australia. Brigid C. Browne's co-authors include John Crown, Norma O’Donovan, Michael J. Duffy, Neil A. O’Brien, Dennis J. Slamon, Jane Arboleda, Yuhua Wang, Lucy Chow, Charles Ginther and Martina S.J. McDermott and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Brigid C. Browne

21 papers receiving 958 citations

Peers

Brigid C. Browne

ONCOL

RNMI

PRM

Rumey C. Ishizawar United States

Jane Arboleda United States

Rebecca S. Muraoka-Cook United States

Josep-Lluís Parra Spain

Isabel Martínez-Lacaci Spain

Tim P. Green United Kingdom

Maria G. Olivares United States

Jonathan R. Reeves United Kingdom

Leanne Berry United States

Kedar S. Vaidya United States

Rumey C. Ishizawar United States

Brigid C. Browne

436 ×0.8

ONCOL

600 ×1.1

113 ×0.6

RNMI

111 ×0.9

170 ×1.5

PRM

Citations per year, relative to Brigid C. Browne Brigid C. Browne (= 1×) peers Rumey C. Ishizawar

Countries citing papers authored by Brigid C. Browne

Since Specialization

Citations

This map shows the geographic impact of Brigid C. Browne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigid C. Browne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigid C. Browne more than expected).

Fields of papers citing papers by Brigid C. Browne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigid C. Browne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigid C. Browne. The network helps show where Brigid C. Browne may publish in the future.

Co-authorship network of co-authors of Brigid C. Browne

This figure shows the co-authorship network connecting the top 25 collaborators of Brigid C. Browne. A scholar is included among the top collaborators of Brigid C. Browne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brigid C. Browne. Brigid C. Browne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McDermott, Martina S.J., Neil T. Conlon, Brigid C. Browne, et al.. (2019). HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells. Cancers. 11(2). 197–197. 33 indexed citations

Canonici, Alexandra, Neil T. Conlon, Kasper Pedersen, et al.. (2018). HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. Investigational New Drugs. 37(3). 441–451. 21 indexed citations

Conlon, Neil T., Martina S.J. McDermott, Brigid C. Browne, et al.. (2018). Pre-clinical evaluation of the PP2A inhibitor LB-100 for the treatment of lapatinib resistant HER2-positive breast cancer.. Journal of Clinical Oncology. 36(15_suppl). e13021–e13021. 1 indexed citations

McDermott, Martina S.J., Alexandra Canonici, Brigid C. Browne, et al.. (2017). Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells. International Journal of Oncology. 50(6). 2221–2228. 24 indexed citations

Guibourdenche, M, Brigid C. Browne, Lorraine O’Driscoll, et al.. (2017). Alterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (T-ADCC) in a lapatinib-resistant HER2+ breast cancer cell line model. Annals of Oncology. 28. v4–v4. 1 indexed citations

McDermott, Martina S.J., et al.. (2016). Irreversible panHER tyrosine kinase inhibitors (TKIs) to induce irreversible senescence in HER2 positive breast cancer cells.. Journal of Clinical Oncology. 34(15_suppl). e12092–e12092. 3 indexed citations

Rani, Sweta, Claire Corcoran, Serena Germano, et al.. (2014). Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors. Cancer Research. 74(14). 3821–3833. 39 indexed citations

Croucher, David R., Falko Hochgräfe, Luxi Zhang, et al.. (2013). Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway. Cancer Research. 73(6). 1969–1980. 67 indexed citations

Browne, Brigid C., Alex J. Eustace, Susan Kennedy, et al.. (2012). Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Research and Treatment. 136(3). 717–727. 32 indexed citations

10.

Gallego‐Ortega, David, Brigid C. Browne, C. Elizabeth Caldon, et al.. (2012). Functional characterization of cancer-associated Gab1 mutations. Oncogene. 32(21). 2696–2702. 26 indexed citations

11.

McDermott, Martina S.J., Brigid C. Browne, Dennis J. Slamon, et al.. (2012). 145 PP2A – a Novel Target for the Treatment of Lapatinib-resistant Breast Cancer. European Journal of Cancer. 48. 45–45. 1 indexed citations

12.

Eustace, Alex J., Brigid C. Browne, Stephen F. Madden, et al.. (2012). Effect of acquired resistance to lapatinib in HER2-positive breast cancer cells on the Bcl-2 family members MCL-1 and BAX.. Journal of Clinical Oncology. 30(15_suppl). 633–633. 1 indexed citations

13.

Eustace, Alex J., Brigid C. Browne, Martina S.J. McDermott, et al.. (2012). 144 Alterations in Apoptosis-related Genes in Cell Line Models of Acquired Lapatinib Resistance, Identifies Potential Therapeutic Targets for the Treatment of Lapatinib Resistant HER2-positive Breast Cancer. European Journal of Cancer. 48. 44–45.

14.

McDermott, Martina S.J., et al.. (2011). Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer cells.. Journal of Clinical Oncology. 29(15_suppl). 583–583. 3 indexed citations

15.

Hochgräfe, Falko, Luxi Zhang, Sandra O’Toole, et al.. (2010). Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells. Cancer Research. 70(22). 9391–9401. 141 indexed citations

16.

Abreu, Maria Teresa Herrera, William E. Hughes, Ruth J. Lyons, et al.. (2010). Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation. Molecular Biology of the Cell. 22(1). 105–116. 20 indexed citations

17.

Browne, Brigid C., John Crown, Natarajan Venkatesan, et al.. (2010). Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Annals of Oncology. 22(1). 68–73. 84 indexed citations

18.

O’Brien, Neil A., Brigid C. Browne, Lucy Chow, et al.. (2010). Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib. Molecular Cancer Therapeutics. 9(6). 1489–1502. 249 indexed citations

19.

Browne, Brigid C., Neil A. O’Brien, Michael J. Duffy, John Crown, & Norma O’Donovan. (2009). HER-2 Signaling and Inhibition in Breast Cancer. Current Cancer Drug Targets. 9(3). 419–438. 92 indexed citations

20.

Ryan, Bríd M., Norma O’Donovan, Brigid C. Browne, et al.. (2004). Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer. British Journal of Cancer. 92(1). 120–124. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact